Cost Effectiveness of Influenza Vaccine Choices in Children Aged 2–8 Years in the U.S

Introduction Prior evidence found live attenuated influenza vaccine (LAIV) more effective than inactivated influenza vaccine (IIV) in children aged 2–8 years, leading CDC in 2014 to prefer LAIV use in this group. However, since 2013, LAIV has not proven superior, leading CDC in 2015 to rescind their...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of preventive medicine 2016-05, Vol.50 (5), p.600-608
Hauptverfasser:	Smith, Kenneth J., MD, MS, Raviotta, Jonathan M., MPH, DePasse, Jay V., BS, Brown, Shawn T., PhD, Shim, Eunha, PhD, Patricia Nowalk, Mary, PhD, RD, Zimmerman, Richard K., MD, MPH
Format:	Artikel
Sprache:	eng
Schlagworte:	Centers for Disease Control and Prevention (U.S.) Child Child, Preschool Cost-Benefit Analysis Humans Influenza Vaccines - administration & dosage Influenza Vaccines - economics Influenza, Human - economics Influenza, Human - prevention & control Internal Medicine Markov Chains Quality-Adjusted Life Years United States Vaccination - economics Vaccination - methods Vaccines, Inactivated - administration & dosage Vaccines, Inactivated - economics Vaccines, Live, Unattenuated - administration & dosage Vaccines, Live, Unattenuated - economics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!